Tadalafil Tablet, Film Coated
Product Images NDC 71205-720

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71205-720). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tadalafil Figure1)

Four line graphs showing the difference in blood pressure measurements (Tadalafil minus Placebo) over time in hours. The graphs display standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure changes with error bars indicating variability at each time point up to 96 hours.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs illustrating changes in systolic blood pressure (BP) over 24 hours post-dose, comparing Tadalafil 20 mg with doxazosin 8 mg and placebo with doxazosin 8 mg. The top graph shows standing systolic BP changes; the bottom graph shows supine systolic BP changes, both measured in mmHg against time in hours.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph depicting changes in systolic blood pressure (mmHg) over time (hours) after administration of tadalafil or placebo. It compares 20 mg tadalafil at 08:00 and 20:00 doses with 8 mg doxazosin at 08:00 versus placebo combined with 8 mg doxazosin, showing four distinct data series based on timing and treatment.*

FDA Label Image

Figure (Tadalafil Figure4)

Pharmacokinetic line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 days. The graph includes error bars indicating variability at each time point, illustrating the changes in tadalafil levels in plasma up to 120 hours post-dose.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS Total Score over 12 weeks of treatment comparing tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in score. The tadalafil group shows a greater decrease in score than placebo, with statistical significance indicated at 12 weeks.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment for tadalafil 5 mg versus placebo. The x-axis represents treatment duration in weeks; the y-axis shows the change in IPSS total score. Tadalafil demonstrates a greater decrease in score compared to placebo, with statistical significance indicated at certain points.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph depicting the least squares mean change from baseline over 26 weeks of therapy for two groups: Tadalafil/Finasteride and Placebo/Finasteride. The vertical axis shows the change from baseline, while the horizontal axis indicates weeks of therapy at 0, 4, 12, and 26 weeks. Data points with significance indicators (p<0.001 and p<0.05) are shown for comparison of treatment effects.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph depicting change from baseline in IPSS total score over duration of treatment in weeks. Two lines represent tadalafil 5 mg and placebo groups, showing a greater decrease in score for the tadalafil group compared to placebo over 12 weeks, with statistical significance noted at week 12.*

FDA Label Image

71205-720-04 (Tadalafil Label 10mg)

Label for Tadalafil Tablets USP, 10 mg, film-coated tablets in a package of 4 tablets. The label includes directions that tablets should not be split and the entire dose should be taken. Manufactured by Intas Pharmaceuticals Limited and packaged by Proficient Rx LP. The label mentions storage instructions and a warning to keep out of reach of children.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of tadalafil, showing its molecular framework with multiple rings including a benzodioxole group and a methylated diketopiperazine ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.